You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarboprost Tromethamine
Accession NumberDB00429  (APRD00847)
TypeSmall Molecule
GroupsApproved
DescriptionA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy. [PubChem]
Structure
Thumb
Synonyms
(15S)-15-Methyl-pgf2alpha tromethamine salt
(15S)-15-Methylprostaglandin F2alpha tromethamine
1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9alpha,11beta,13e,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate
15(S)-15-Methyl-pgf2alpha tromethamine salt
15(S)-15-Methylprostaglandin F2alpha tromethamine
Carboprost
Carboprost trometamol
Methyldinoprost
External Identifiers
  • U 32921 E
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HemabateSolution250 mcgIntramuscularPfizer Canada Inc1997-11-28Not applicableCanada
HemabateInjection, solution250 ug/mLIntramuscularPharmacia And Upjohn Company Llc1979-01-09Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarboprostNot Available
DeviprostDr. Reddy's
Prostin 15MPfizer
ProstinfenemPfizer
ProstodinAstraZeneca
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIU4526F86FJ
CAS number58551-69-2
WeightAverage: 489.6426
Monoisotopic: 489.330167485
Chemical FormulaC25H47NO8
InChI KeyUMMADZJLZAPZAW-OVXHCKHTSA-N
InChI
InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19+,21+;/m1./s1
IUPAC Name
1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z)-7-[(1R,2R,3S,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hept-5-enoate
SMILES
OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[[email protected]]1[C@@H](O)C[[email protected]](O)[C@@H]1C\C=C/CCCC(=O)[O-]
Pharmacology
IndicationFor aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.
Structured Indications
PharmacodynamicsCarboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Whether or not these contractions result from a direct effect of carboprost on the myome-trium has not been determined. Nonetheless, they evacuate the products of conception from the uterus in most cases. Postpartum, the resultant myometrial contractions provide hemostasis at the site of placentation. Carboprost tromethamine also stimulates the smooth muscle of the human gastrointestinal tract. This activity may produce the vomiting or diarrhea or both that is common when carbo-prost tromethamine is used to terminate pregnancy and for use postpartum. In laboratory animals and also in humans carboprost tromethamine can elevate body temperature. With the clinical doses of carboprost trometh-amine used for the termination of pregnancy, and for use postpartum, some patients do experience transient temperature increases. In laboratory animals and in humans large doses of carboprost tromethamine can raise blood pressure, probably by contracting the vascular smooth muscle. With the doses of carboprost tromethamine used for terminating pregnancy, this effect has not been clinically significant. In laboratory animals and also in humans carboprost tromethamine can elevate body temperature. With the clinical doses of carboprost tromethamine used for the termination of pregnancy, some patients do experience temperature increases. In some patients, carboprost tromethamine may cause transient bronchoconstriction.
Mechanism of actionCarboprost is a synthetic prostaglandin. It binds the prostaglandin E2 receptor, causing myometrial contractions, casuing the induction of labour or the expulsion of the placenta. Prostaglandins occur naturally in the body and act at several sites in the body including the womb (uterus). They act on the muscles of the womb, causing them to contract.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin E2 receptor EP1 subtypeProteinyes
agonist
HumanP34995 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized in the lungs and liver. Metabolites are excreted in urine.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include irritation, nausea, vomiting, diarrhea, coughing, dyspnea, asthma, hypertension, flushing, and pyrexia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Aceclofenac.Approved
AcetovanilloneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Adapalene.Approved
AnisodamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Antipyrine.Approved
ApremilastThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Apremilast.Approved, Investigational
AsoprisnilThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Asoprisnil.Investigational
AzapropazoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Balsalazide.Approved, Investigational
BenoxaprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Benoxaprofen.Withdrawn
Betulinic AcidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Betulinic Acid.Investigational
BromfenacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bucillamine.Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Carbetocin.Approved
CarprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Celecoxib.Approved, Investigational
ChloroquineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ClonixinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Clonixin.Approved
CurcuminThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Curcumin.Investigational
D-LimoneneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with D-Limonene.Investigational
DiclofenacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiflunisalThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diflunisal.Approved
DinoprostThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Dinoprost.Investigational
Dinoprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Dinoprost Tromethamine.Approved, Vet Approved
DinoprostoneThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Dinoprostone.Approved
DroxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ebselen.Investigational
EpirizoleThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Epirizole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergotamine.Approved
EtanerceptThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etanercept.Approved, Investigational
EtodolacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with exisulind.Investigational
FenbufenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenoprofen.Approved
FloctafenineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Flunixin.Vet Approved
FlurbiprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
HigenamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with HMPL-004.Investigational
IbuprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Icatibant.Approved
IndomethacinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indoprofen.Withdrawn
IsoxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Kebuzone.Experimental
KetoprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketorolac.Approved
LeflunomideThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Leflunomide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lisofylline.Investigational
LornoxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved
LoxoprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Masoprocol.Approved
Meclofenamic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole.Withdrawn
MethylergometrineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Methylergometrine.Approved
MisoprostolThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Misoprostol.Approved
MizoribineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mizoribine.Investigational
Mycophenolate mofetilThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Naftifine.Approved
NaproxenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with NCX 4016.Investigational
NepafenacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nepafenac.Approved
Niflumic AcidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NitroaspirinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nitroaspirin.Investigational
OlopatadineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine.Approved
OrgoteinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxytocinThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Oxytocin.Approved, Vet Approved
ParecoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Parecoxib.Approved
PhenylbutazoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pirfenidone.Investigational
PiroxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Piroxicam.Approved, Investigational
PropacetamolThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Propacetamol.Approved
PTC299The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with PTC299.Investigational
ResveratrolThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.Experimental, Investigational
RofecoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SalicylamideThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salsalate.Approved
SeratrodastThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Seratrodast.Approved, Investigational
SparteineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Sparteine.Experimental
SRT501The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Suprofen.Approved, Withdrawn
TenoxicamThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved
TinoridineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tinoridine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolmetin.Approved
TranilastThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tranilast.Approved, Investigational
Trisalicylate-cholineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Trisalicylate-choline.Approved
ValdecoxibThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Ming Li, “CRYSTALS OF CARBOPROST TROMETHAMINE AND THE PREPARATION METHOD AS WELL AS THE USES THEREOF.” U.S. Patent US20130190404, issued July 25, 2013.

US20130190404
General ReferencesNot Available
External Links
ATC CodesG02AD04
AHFS Codes
  • 76:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (49.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5755
Blood Brain Barrier-0.5581
Caco-2 permeable-0.6594
P-glycoprotein substrateSubstrate0.6894
P-glycoprotein inhibitor INon-inhibitor0.9445
P-glycoprotein inhibitor IINon-inhibitor0.9643
Renal organic cation transporterNon-inhibitor0.8922
CYP450 2C9 substrateNon-substrate0.8241
CYP450 2D6 substrateNon-substrate0.7916
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.7693
CYP450 2C9 inhibitorNon-inhibitor0.8874
CYP450 2D6 inhibitorNon-inhibitor0.7649
CYP450 2C19 inhibitorNon-inhibitor0.8534
CYP450 3A4 inhibitorNon-inhibitor0.943
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.933
Ames testNon AMES toxic0.9008
CarcinogenicityNon-carcinogens0.9422
BiodegradationReady biodegradable0.5
Rat acute toxicity2.4308 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9511
hERG inhibition (predictor II)Non-inhibitor0.9008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular250 ug/mL
SolutionIntramuscular250 mcg
Prices
Unit descriptionCostUnit
Hemabate 250 mcg/ml ampul92.89USD ml
Tham iv solution0.49USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point95-105 °CNot Available
water solubilityCarboprost tromethamine dissolves readily in water at room temperature at a concentration greater than 75 mg/mL.Not Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0622 mg/mLALOGPS
logP1.07ALOGPS
logP2.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.36ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.82 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity115.95 m3·mol-1ChemAxon
Polarizability42.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Long-chain fatty acid
  • Hydroxy fatty acid
  • Carbocyclic fatty acid
  • Branched fatty acid
  • Fatty acid
  • Unsaturated fatty acid
  • Cyclopentanol
  • Tertiary alcohol
  • Quaternary ammonium salt
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid salt
  • 1,2-aminoalcohol
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic zwitterion
  • Aliphatic homomonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Hay A, Wood S, Olson D, Slater DM: Labour is associated with decreased expression of the PGF2alpha receptor (PTGFR) and a novel PTGFR splice variant in human myometrium but not decidua. Mol Hum Reprod. 2010 Oct;16(10):752-60. doi: 10.1093/molehr/gaq046. Epub 2010 Jun 2. [PubMed:20519365 ]
  3. Tsuboi K, Ichikawa A: [Reproduction physiology and prostanoids]. Nihon Yakurigaku Zasshi. 2001 Apr;117(4):267-73. [PubMed:11338376 ]
  4. Carrasco MP, Asboth G, Phaneuf S, Lopez Bernal A: Activation of the prostaglandin FP receptor in human granulosa cells. J Reprod Fertil. 1997 Nov;111(2):309-17. [PubMed:9462300 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23